Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics

The identification of heterozygous neomorphic isocitrate dehydrogenase (IDH) mutations across multiple cancer types including both solid and hematologic malignancies has revolutionized our understanding of oncogenesis in these malignancies and the potential for targeted therapeutics using small mole...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Front Oncol
Hoofdauteurs: Golub, Danielle, Iyengar, Nishanth, Dogra, Siddhant, Wong, Taylor, Bready, Devin, Tang, Karen, Modrek, Aram S., Placantonakis, Dimitris G.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Frontiers Media S.A. 2019
Onderwerpen:
Oncology
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6534082/
https://ncbi.nlm.nih.gov/pubmed/31165048
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00417
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items